Xtant Medical Reports Financial Success for First Quarter
Xtant Medical Holdings, Inc. (NYSE American: XTNT), recognized for its innovation in medical technology, has announced impressive financial results for the first quarter of 2025. The company has demonstrated strong growth, achieving an 18% increase in revenue compared to the previous year, with revenue reaching $32.9 million. This growth is reflective of Xtant Medical's steadfast commitment to enhancing surgical solutions for spinal, orthopedic, and wound care treatments.
Key Financial Highlights for the Quarter
During this quarter, Xtant Medical achieved several significant financial milestones:
- Revenue surged to $32.9 million, marking an 18% increase year-over-year.
- The gross margin was reported at 61.5%, slightly down from 62.1% in the previous year.
- The company recorded net income of $58,000, a remarkable turnaround from a loss of $4.4 million in Q1 2024.
- Adjusted EBITDA reached $3 million, a substantial improvement over an adjusted EBITDA loss of $1 million.
- Xtant Medical generated $1.3 million in cash from operations as opposed to $5.8 million utilized in operations during the same period last year.
Strategic Business Developments
Xtant Medical has also made notable advancements within its business framework:
- The launch of Trivium™, a new premium demineralized bone matrix allograft, signifies the company's drive to elevate standards in orthobiologic care.
- The completion of a secondary private stock sale led by OrbiMed Advisors LLC has facilitated enhanced liquidity for corporate strategies.
- The termination of the investor rights agreement with OrbiMed grants Xtant Medical greater flexibility in governance.
- Mark Schallenberger has been appointed as the new Chief Operating Officer, a strategic move to fortify the company’s operational leadership.
Management Insights
Sean Browne, President and CEO, expressed his enthusiasm about the quarter's results, indicating that they illustrate a robust execution of the company’s strategic plan. He noted, "Our 18% revenue growth showcases our advancements in biologics and reflects fruitful agreements we’ve entered recently. Moreover, attaining positive cash flow positions us well for future growth without necessitating additional capital." Browne emphasized the promising early feedback on Trivium™ from surgeons and partners, positioning it as a catalyst for further revenue enhancement.
Outlook for 2025
Xtant Medical has increased its revenue guidance for the full year 2025, now forecasting total revenue between $127 million and $131 million. This revised estimation represents an anticipated growth of 8% to 12%, up from prior guidance set between $126 million and $130 million.
Conference Call Plans
A conference call is scheduled for Xtant Medical to further discuss its first quarter financial results. Interested parties are encouraged to join the call, which will provide deeper insights into the company’s performance and future directives.
About Xtant Medical Holdings, Inc.
Xtant Medical is devoted to respecting the gifts of organ donation to foster healthier lives for patients undergoing surgical procedures. The company specializes in designing and developing a versatile portfolio of orthobiologics and spinal implant systems aimed at facilitating complex spine surgeries.
Frequently Asked Questions
1. What were the key financial highlights for Xtant Medical in Q1 2025?
Xtant Medical achieved $32.9 million in revenue, an 18% increase from the prior year, positive net income of $58,000, and generated $1.3 million in cash from operations.
2. What is Trivium™, and why is it significant for Xtant Medical?
Trivium™ is a premium demineralized bone matrix allograft launched by Xtant Medical. It represents a significant improvement in orthobiologic solutions that the company believes will drive future growth.
3. Who is the new COO of Xtant Medical?
Mark Schallenberger has been appointed as the Chief Operating Officer to enhance the company’s operational management.
4. How has Xtant Medical’s revenue guidance changed for 2025?
The forecast for 2025 revenue has been raised to between $127 million and $131 million, indicating expected growth between 8% to 12%.
5. When will Xtant Medical hold its conference call regarding its financial results?
A conference call is set to occur soon after the release of the financial results, allowing stakeholders to gain more insight into the company's future strategies.
